NASDAQ:TCDATricida Stock Price, Forecast & News

Tricida's stock was trading at $28.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TCDA stock has decreased by 49.4% and is now trading at $14.18.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Tricida.

Tricida is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Tricida.

Tricida Inc (NASDAQ:TCDA) issued its quarterly earnings results on Wednesday, August, 5th. The company reported ($1.16) EPS for the quarter, topping the consensus estimate of ($1.46) by $0.30.
View Tricida's earnings history.

2 brokers have issued 12-month target prices for Tricida's stock. Their forecasts range from $40.00 to $44.00. On average, they expect Tricida's share price to reach $42.00 in the next year. This suggests a possible upside of 196.2% from the stock's current price.
View analysts' price targets for Tricida.

News articles about TCDA stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Tricida earned a news sentiment score of -1.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about Tricida.

Some companies that are related to Tricida include Pacira Biosciences (PCRX), Taro Pharmaceutical Industries (TARO), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Apellis Pharmaceuticals (APLS), TG Therapeutics (TGTX), Prestige Consumer Healthcare (PBH), Xencor (XNCR), Uniqure (QURE), Ligand Pharmaceuticals (LGND), Aurinia Pharmaceuticals (AUPH), Intercept Pharmaceuticals (ICPT), IGM Biosciences (IGMS), I-Mab (IMAB) and Eidos Therapeutics (EIDX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Gilead Sciences (GILD), Myovant Sciences (MYOV), VBI Vaccines (VBIV), Atara Biotherapeutics (ATRA), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), Matinas BioPharma (MTNB), Pfizer (PFE), AbbVie (ABBV) and Agile Therapeutics (AGRX).

(TCDA) raised $175 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Tricida's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.24%), Cormorant Asset Management LP (1.74%), Federated Hermes Inc. (0.76%), Artal Group S.A. (0.57%), New York State Common Retirement Fund (0.46%) and Alyeska Investment Group L.P. (0.40%). Company insiders that own Tricida stock include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Orbimed Advisors Llc, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP and Wilhelm Stahl.
View institutional ownership trends for Tricida.

TCDA stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Goldman Sachs Group Inc., California Public Employees Retirement System, Cormorant Asset Management LP, PDT Partners LLC, Bank of America Corp DE, and Ikarian Capital LLC. Company insiders that have sold Tricida company stock in the last year include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Gerrit Klaerner, Klaus R Dr Veitinger, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP, and Wilhelm Stahl.
View insider buying and selling activity for Tricida.

TCDA stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., New York State Common Retirement Fund, Federated Hermes Inc., Alyeska Investment Group L.P., Tekla Capital Management LLC, SG Americas Securities LLC, Barclays PLC, and Russell Investments Group Ltd.. Company insiders that have bought Tricida stock in the last two years include Geoffrey M Parker, and Orbimed Advisors Llc.
View insider buying and selling activity for Tricida.

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TCDA stock can currently be purchased for approximately $14.18.

Tricida has a market capitalization of $709.69 million. The company earns $-176,810,000.00 in net income (profit) each year or ($3.72) on an earnings per share basis. Tricida employs 76 workers across the globe.

The official website for Tricida is www.tricida.com.

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]